The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas
- PMID: 35430032
- DOI: 10.1016/S2468-1253(22)00008-5
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects 20-25% of the general population and is associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD risk factors are modifiable and, therefore, potentially amenable to being reduced by public health policies. To date, there is no information about NAFLD-related public health policies in the Americas. In this study, we analysed data from 17 American countries and found that none have established national public health policies to decrease NAFLD-related burden. There is notable heterogeneity in the existence of public health policies to prevent NAFLD-related conditions. The most common public health policies were related to diabetes (15 [88%] countries), hypertension (14 [82%] countries), cardiovascular diseases (14 [82%] countries), obesity (nine [53%] countries), and dyslipidaemia (six [35%] of countries). Only seven (41%) countries had a registry of the burden of NAFLD, and efforts to raise awareness in the Americas were scarce. The implementation of public health policies are urgently needed in the Americas to decrease the burden of NAFLD.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests NC-T received speaking fees from Bayer. The other authors declare no conflicts of interest.
Similar articles
-
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10. J Hepatol. 2020. PMID: 31518646
-
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?J Hepatol. 2022 Apr;76(4):771-780. doi: 10.1016/j.jhep.2021.10.025. Epub 2021 Dec 9. J Hepatol. 2022. PMID: 34895743 Review.
-
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156
-
NAFLD: Challenges and opportunities to address the public health problem in Latin America.Ann Hepatol. 2021 Sep-Oct;24:100359. doi: 10.1016/j.aohep.2021.100359. Epub 2021 May 15. Ann Hepatol. 2021. PMID: 34004366
-
The prevalence of nonalcoholic fatty liver disease in the Americas.Ann Hepatol. 2014 Mar-Apr;13(2):166-78. Ann Hepatol. 2014. PMID: 24552858 Review.
Cited by
-
Global epidemiology of cirrhosis - aetiology, trends and predictions.Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36977794 Free PMC article. Review.
-
Public Health Measures and Prevention of Alcohol-Associated Liver Disease.J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1480-1491. doi: 10.1016/j.jceh.2022.05.005. Epub 2022 May 31. J Clin Exp Hepatol. 2022. PMID: 36340308 Free PMC article. Review.
-
Tea intake and non-alcoholic fatty liver disease risk: A two-sample Mendelian randomization study.Metabol Open. 2024 Sep 24;24:100322. doi: 10.1016/j.metop.2024.100322. eCollection 2024 Dec. Metabol Open. 2024. PMID: 39399721 Free PMC article.
-
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):764-783. doi: 10.1038/s41575-023-00822-y. Epub 2023 Aug 15. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37582985 Review.
-
Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.Cell Mol Gastroenterol Hepatol. 2024;17(3):399-421. doi: 10.1016/j.jcmgh.2023.11.014. Epub 2023 Nov 29. Cell Mol Gastroenterol Hepatol. 2024. PMID: 38036082 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical